Major Events - Fosun Pharma (02196) has had its drug registration application for Fumainin® accepted [1] - Hengrui Medicine (01276) has received approval for clinical trials of 9 drugs [1] - China Jinmao (00817) subsidiary plans to sell 100% equity of Jinmao (Sanya) Tourism Co., Ltd. with a base price of 2.2646 billion yuan [1] - Boleton (01333) has launched a new unmanned mining truck [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval for selective 5-HT2A receptor agonist (SYH2056 tablets) in China [1] - Beijing Automotive (01958) plans to sell 51% equity of Beiqi International for approximately 1.608 billion yuan [1] - CITIC Bank (00998) has received approval for its wholly-owned subsidiary, Xinyin Jintou, to commence operations [1] Operating Performance - Miniso Group (09896) reported a third-quarter adjusted net profit of 767 million yuan, an increase of 11.7% year-on-year [1] - Puda Tech (00650) achieved sales revenue of approximately 77.568 million Hong Kong dollars in the first half, securing significant orders for several core semiconductor equipment products [1] - Youju Holdings (01948) reported total billing of approximately 11.863 billion yuan from online marketing solutions in the first nine months, a year-on-year increase of about 35.3% [1] - Nanxuan Holdings (01982) announced a mid-term profit attributable to shareholders of 336 million Hong Kong dollars, a year-on-year growth of 12.7% [1] - International Commercial Settlement (00147) issued a profit warning, expecting a year-on-year increase of approximately 72% in mid-term comprehensive net loss [1]

格隆汇11月21日丨石药集团(01093.HK)宣布，集团开发的化药1类新药选择性5-羟色胺2A受体(「5- HT2A受体」)激动剂(SYH2056片)(「该产品」)已获得中华人民共和国国家药品监督管理局批准，可在 中国开展临床试验。 鉴于传统抗抑郁药物存在较多无法克服的临床治疗不足，且抑郁障碍缺乏新机制的药物治疗，该产品的 临床需求广阔，具有较高的临床开发价值。 该产品为一种选择性5-HT2A受体激动剂，通过激活该受体改善抑郁障碍患者的疾病状态，单次给药即 可快速起效，药效持久，且不产生致幻风险。本次获批的临床适应症为用于治疗抑郁症。临床前研究显 示，该产品可有效促进中枢神经元的树突与树突棘生成，具有促进神经重塑作用。在多种抑郁动物模型 中，该产品表现出优异的抗抑郁活性，并且极大地降低了该靶点可能存在的致幻风险，同时具有良好的 药代动力学(PK)特性和安全性，使其具备成为一款同类最优(best-in-class)抗抑郁药物的潜力。目前，集 团已在国内外提交了该产品的多项专利申请。 ...

Core Viewpoint - The announcement highlights that the pharmaceutical company, Shiyao Group, has received approval from the National Medical Products Administration of China to conduct clinical trials for its novel Class 1 chemical drug, SYH2056, a selective 5-HT2A receptor agonist aimed at treating depression [1] Group 1: Product Details - SYH2056 is a selective 5-HT2A receptor agonist that improves the condition of patients with depressive disorders by activating the receptor, showing rapid onset of action and prolonged efficacy without causing hallucinogenic risks [1] - The approved clinical indication for SYH2056 is for the treatment of depression, with preclinical studies demonstrating its effectiveness in promoting the generation of dendrites and dendritic spines in central nervous neurons, indicating a potential for neuroplasticity [1] - In various animal models of depression, SYH2056 exhibited excellent antidepressant activity while significantly reducing the potential hallucinogenic risks associated with the target, along with favorable pharmacokinetic (PK) properties and safety, positioning it as a potential best-in-class antidepressant [1] Group 2: Market Potential - Given the numerous clinical treatment inadequacies of traditional antidepressants and the lack of new mechanism drug therapies for depressive disorders, SYH2056 has a broad clinical demand and high clinical development value [1]